Browsing publications by Dr Andrew Gennery

Newcastle AuthorsTitleYearFull text
Dr Katherine Sturgess
Dr Rachel Dickinson
Dr Andrew Gennery
Professor Andrew Cant
Professor Graham Jackson
et al.
In vivo T-depleted reduced intensity transplantation for GATA2-related immune dysfunction.2018
Dr Tom Altmann
Dr James Slack
Dr Mary Slatter
Professor Andrew Cant
Dr Matthew Thomas
et al.
Endothelial cell damage in idiopathic pneumonia syndrome2018
Dr Mary Slatter
Dr Andrew Gennery
Hematopoietic cell transplantation in primary immunodeficiency–conventional and emerging indications2018
Dr Zohreh Nademi
Dr Mary Slatter
Dr Andrew Gennery
Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study2018
Dr Aisling Flinn
Dr Mary Slatter
Professor Roderick Skinner
Dr Andrew Gennery
Thymopoiesis following HSCT; a retrospective review comparing interventions for aGVHD in a pediatric cohort2018
Dr Andrew Gennery
A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome2017
Dr Mary Slatter
Dr Andrew Gennery
Approaches to the removal of T-lymphocytes to minimize graft-versus-host disease in patients with primary immunodeficiencies who do not have a matched sibling donor2017
Dr Venetia Bigley
Dr Urszula Cytlak-Chaudhuri
Dr Laura Jardine
Kile Green
Dr Merry Gunawan
et al.
Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation2017
Dr Andrew Gennery
Corrigendum: Natural killer cells from patients with recombinase-activating gene and non-homologous end joining gene defects comprise a higher frequency of CD56bright NKG2A+++ cells, and yet display increased degranulation and higher perforin content [Front Immunol, 8, (2017), (798)] doi: 10.3389/fimmu.2017.007982017
Dr Andrew Gennery
Dr Mary Slatter
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT2017
1234567891011121314151617181920...